Trials / Recruiting
RecruitingNCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)/Anti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Conditions
- Systemic Lupus Erythematosus (SLE)
- Immune-mediated Necrotizing Myopathy (IMNM)
- Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Multiple Sclerosis (MS)
- Myasthenia Gravis
- Systemic Sclerosis (SSc)
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD20/BCMA-directed CAR-T cells | Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2027-03-01
- Completion
- 2040-03-01
- First posted
- 2024-02-08
- Last updated
- 2025-07-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06249438. Inclusion in this directory is not an endorsement.